Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men

Massimo Giuliani; Alessandra Latini; Manuela Colafigli; Maria Benevolo; Francesca Rollo; Mauro Zaccarelli; Eugenia Giuliani; Domenico Moretto; Amalia Giglio; Giovanni Rezza; Antonio Cristaudo; Maria G Donà

doi:10.2217/fmb-2018-0149

Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men

Future Microbiol. 2018 Oct:13:1463-1472. doi: 10.2217/fmb-2018-0149. Epub 2018 Oct 12.

Affiliations

¹ HIV/STI Unit, Clinical and Experimental Dermatology Department, San Gallicano Dermatological Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
² Pathology Department, Regina Elena National Cancer Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
³ Clinical and Research Department, Istituto Nazionale Malattie Infettive INMI Lazzaro Spallanzani IRCCS, Via Portuense, 292, 00149, Rome, Italy.
⁴ Department of Molecular Medicine, Sapienza University, Viale Regina Elena, 291-293 00161, Rome, Italy.
⁵ Microbiology & Clinical Pathology Department, San Gallicano Dermatological Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
⁶ Department of Infectious, Parasitic & Immune-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00141, Rome, Italy.

PMID: 30311788
DOI: 10.2217/fmb-2018-0149

Abstract

Aim: HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population.

Materials & methods: Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test.

Results: A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes.

Conclusion: A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated.

Keywords: HIV; HPV; MSM; anal; vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anal Canal / virology
Anus Diseases / diagnosis
Anus Diseases / epidemiology
Anus Diseases / prevention & control
Anus Diseases / virology*
Cohort Studies
HIV / genetics
HIV / immunology
HIV Infections / diagnosis
HIV Infections / epidemiology
HIV Infections / virology
Homosexuality, Male*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / immunology
Humans
Incidence
Male
Papillomaviridae / genetics*
Papillomaviridae / immunology
Papillomavirus Infections / diagnosis
Papillomavirus Infections / epidemiology
Papillomavirus Infections / prevention & control
Papillomavirus Infections / virology*
Prevalence
Prospective Studies
Sexually Transmitted Diseases / diagnosis
Sexually Transmitted Diseases / epidemiology
Sexually Transmitted Diseases / prevention & control
Sexually Transmitted Diseases / virology*

Substances

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18